Checklist de Festuca L. (Poaceae) en la Península Ibérica

Se ha elaborado una checklist actualizada del género Festuca en la Pe¬nínsula Ibérica. El catálogo incluye 73 especies, que suman 98 taxones si se consideran las subespecies y variedades, de los que casi el 40% son endémicos del territorio. Para cada taxón se recoge el nombre válido y las sinonimias más importantes, la indicación locotípica, el número cromosómico, las características ecológicas, la distribución general y en el territorio, y la información bibliográfica de interés. Además, se recogen en varios apéndices los nombres sin asignación, los híbridos interespecíficos detectados en el territorio, los híbridos intergenéricos conocidos, los taxones excluidos provisionamente y aquellos cuya presencia es probable en el territorio.Checklist of Festuca L. (Poaceae) in the Iberian Peninsula. We present an updated checklist of the genus Festuca in the Iberian Peninsula. The catalogue includes 73 species, suming up 98 taxa considering infraspecific taxa (subspecies and varieties). Of them, approximately 40% are endemic to the region. Information about the valid name and the most important synonyms, the locus classicus reference, the chromosome number, the ecology, the global and regional geographical distributions, and the most relevant bibliographic references is provided for each taxon. Additional information on the taxa without clear taxonomic assignation, the interspecific hybrids detected in the territory, the described intergeneric hybrids, and the taxa provisionally excluded from the Iberian checklist and those that could be present in the Iberian Peninsula is indicated in the appendices

Microflora associated with healthy and diseased turbot (Scophthalmus maximus) from three farms in northwest Spain

14 páginas, 4 tablas, 3 figurasA comparative analysis of the microbiological quality of three turbot (Scophthabnus maximus) farms (A, B, and C) located in Galicia (northwest Spain) is given. The microbial load and types of bacteria in the internal organs (liver and kidney) of apparently healthy fish was monitored over a year, and all the disease problems occurring during this survey were analyzed. The percentage of healthy turbot in which positive bacterial growth was obtained was relatively high in the three ongrowing facilities. Farm A exhibited the poorest conditions of fish health with an average of 42% fish infected, while farm B showed the best microbiological quality with 27% of turbot harbouring bacteria in the internal organs. In all three farms, a wide range of bacteria was found in healthy turbot with Vibrio ( V. splendidus-V pelagius, Vjisheri-V harveyi and Vibrio spp.) and Pseudomonas spp. being the predominant groups comprising at least 80% of the total bacterial isolates in each farm. The highest number of pathological problems (22 ) with the most diverse bacterial flora occurred in farm A. Vibrio spp. and Pseudomonas spp. were the most prevalent bacteria recovered from diseased turbot. Haemorrhages in palate and jaws, tail and fins, and ulcerative lesions were the most frequent external clinical signs of diseased fish recorded in the three farms. However, it was not possible to associate a particular bacterial species with a specific pathology. Routine use in farm A of oxolinic acid and nitrofurantoin may have led to the development in the Vibrio strains of resistances to both chemotherapeutants (up to 25%).This study was supported by Grants MAR 9 l- 1133~CO2-0 1 and MAR 89- 0270 from the Comision Interministerial de Ciencia y Tecnologia (CICYT), XUGA 8030389 from Xunta de Galicia (Spain), and EUREKA project No. EU-347, between Spain and Norway.Peer reviewe

Financial crisis and pension reform in Spain:the effect of labour market dynamics

We analyse the effect of post-financial crisis unemployment dynamics on the Spanish pension system’s financial health using Aggregate Accounting. We compare the basic scenario where the current labour market dynamics persist with a full employment (best-case) scenario. We find that economic risk is the main driver of unsustainability in the short run. However, in the long run, the main driver of expenditures lies in the ageing demographic structure. Our results suggest that future reforms should increase labour market participation but confirm that recent pension reforms do not attain sustainability in the long run, indicating the need of further pension reforms

High prevalence of secondary resistance mutations in Venezuelan HIV-1 isolates.

The genetic variability was studied in HIV-1 from Venezuelan patients with and without treatment, in order to evaluate the presence of polymorphisms and drug resistance mutations. Proviral DNA from peripheral blood mononuclear cells or viral RNA from plasma was extracted from the blood of 30 patients. Two regions from the polymerase gene, protease (Pr) and reverse transcriptase (RT) and one genomic fragment from the envelope (Env) gene were amplified and sequenced. All HIV-1 samples analyzed were classified as subtype B, without evidence of recombination. Although no primary protease mutations were detected, a high frequency of secondary mutations (86%, 19/22), associated to restoration of viral replicative fitness, was observed in strains circulating both in treated and non-treated patients. Resistance mutations to nucleoside RT inhibitors (NRTI) and non-nucleoside RT inhibitors (NNRTI) were detected in 35% (6/17) and 12% (2/17) of the viruses circulating in treated patients, respectively. Resistance mutations were also present in the virus infecting one antiretroviral naive individual (7.7%), suggesting that local screening for resistant mutation in naive patient might be important to minimize therapy failure. Future studies are warranted to assess the role of secondary mutation in the success of viral infection

Losing silence, gaining acceptance:A qualitative exploration of the role of thoughts in adult patients with subjective tinnitus

Objective: Tinnitus is one of the most common somatic symptoms to affect humanity. Prevalence rates in adult populations range from 8.2 to 20.1%. Our aim was to understand the beliefs and interpretations of tinnitus and the experience of living with it. Design: An in depth grounded theory interview study. Grounded theory is an inductive approach to developing theory. Sample: Thirteen contrasting people with tinnitus who had sought help from clinical services in England. Results: We identified that the thinking patterns that people held around their tinnitus impacted how they experienced it. A core category emerged from the data, “sense making”. Around “sense making” eight other themes operated. Results are discussed in relation to the literature on tinnitus acceptance and beliefs. Conclusions: The aim of interventions is to foster understanding and enhance perceptions of control, which may minimise the emotional impact of tinnitus and reduce the perceived severity of consequences

Measurement of the cross-section and charge asymmetry of WW bosons produced in proton-proton collisions at s=8\sqrt{s}=8 TeV with the ATLAS detector

This paper presents measurements of the $W^+ \rightarrow \mu^+\nu$ and $W^- \rightarrow \mu^-\nu$ cross-sections and the associated charge asymmetry as a function of the absolute pseudorapidity of the decay muon. The data were collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with the ATLAS experiment at the LHC and correspond to a total integrated luminosity of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the 1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured with an uncertainty between 0.002 and 0.003. The results are compared with predictions based on next-to-next-to-leading-order calculations with various parton distribution functions and have the sensitivity to discriminate between them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables, submitted to EPJC. All figures including auxiliary figures are available at https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13

Search for chargino-neutralino production with mass splittings near the electroweak scale in three-lepton final states in √s=13 TeV pp collisions with the ATLAS detector

A search for supersymmetry through the pair production of electroweakinos with mass splittings near the electroweak scale and decaying via on-shell W and Z bosons is presented for a three-lepton final state. The analyzed proton-proton collision data taken at a center-of-mass energy of √s=13  TeV were collected between 2015 and 2018 by the ATLAS experiment at the Large Hadron Collider, corresponding to an integrated luminosity of 139  fb−1. A search, emulating the recursive jigsaw reconstruction technique with easily reproducible laboratory-frame variables, is performed. The two excesses observed in the 2015–2016 data recursive jigsaw analysis in the low-mass three-lepton phase space are reproduced. Results with the full data set are in agreement with the Standard Model expectations. They are interpreted to set exclusion limits at the 95% confidence level on simplified models of chargino-neutralino pair production for masses up to 345 GeV

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort

[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical practice in this population. This was a multicenter observational study including cirrhotic patients infected by HCV GT3, treated with sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 patients were included: 98 (47%) treatment‐experienced, 42 (20%) decompensated and 55 (27%) MELD score >10. In 131 (63%), treatment was SOF+DCV and in 77 (37%), SOF/LDV. Overall, 86% received RBV. RBV addition and extension to 24 weeks was higher in the SOF/LDV group (95% vs 80%, P=.002 and 83% vs 72%, P=.044, respectively). A higher percentage of decompensated patients were treated with DCV than LDV (25% vs 12%, P=.013). Overall, SVR12 was 93.8% (195/208): 94% with SOF+DCV and 93.5% with SOF/LDV. SVR12 was achieved in 90.5% of decompensated patients. Eleven treatment failures: 10 relapses and one breakthrough. RBV addition did not improve SVR (RR: 1.08; P=.919). The single factor associated with failure to achieve SVR was platelet count <75×10E9/mL (RR: 3.50, P=.019). In patients with MELD <10, type of NS5A inhibitor did not impact on SVR12 (94% vs 97%; adjusted RR: 0.49). Thirteen patients (6.3%) had serious adverse events, including three deaths (1.4%) and one therapy discontinuation (0.5%), higher in decompensated patients (16.7% vs 3.6%, P<.006). In patients with GT3 infection and cirrhosis, SVR12 rates were high with both SOF+DCV and SOF/LDV, with few serious adverse events

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine patients with histological proof of adenocarcinoma, who had received no more than a single regimen of 5-fluorouracil-based chemotherapy, were randomised to receive either marimastat (10 mg b.d.) or placebo. Patients were treated for as long as was tolerable. The primary endpoint was overall survival with secondary endpoints of time to disease progression and quality of life. At the point of protocol-defined study completion (85% mortality in the placebo arm) there was a modest difference in survival in the intention-to-treat population in favour of marimastat (P=0.07 log-rank test, hazard ratio=1.23 (95% confidence interval 0.98–1.55)). This survival benefit was maintained over a further 2 years of follow-up (P=0.024, hazard ratio=1.27 (1.03–1.57)). The median survival was 138 days for placebo and 160 days for marimastat, with 2-year survival of 3% and 9% respectively. A significant survival benefit was identified at study completion in the pre-defined sub-group of 123 patients who had received prior chemotherapy (P=0.045, hazard ratio=1.53 (1.00–2.34)). This benefit increased with 2 years additional follow-up (P=0.006, hazard ratio=1.68 (1.16–2.44)), with 2-year survival of 5% and 18% respectively. Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07–1.63)). Marimastat treatment was associated with the development of musculoskeletal pain and inflammation. Events of anaemia, abdominal pain, jaundice and weight loss were more common in the placebo arm. This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients. The greatest benefit was observed in patients who had previously received chemotherapy. A further randomised study of marimastat in these patients is warranted